Simponi approved for non-radiographic axial spondyloarthritis

Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).
Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).

Further information
View Simponi drug record
Summary of Product Characteristics
Manufacturer: MSD

The licensed indications for Simponi (golimumab) have been extended to include the treatment of severe active non-radiographic axial spondyloarthritis with objective signs of inflammation in patients who are intolerant of, or unresponsive to, treatment with NSAIDs.

The recommended dose for the new indication is 50mg by sc inj monthly on the same date each month.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Two new steroid inhalers launched

Two new steroid inhalers launched

A new beclometasone metered-dose inhaler and a new...

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients on statins do not reach cholesterol goals, study shows

Half of patients prescribed statins fail to reach their...

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

First oral hypoglycaemic licensed for add-on therapy in type I diabetes

The SGLT2 inhibitor dapagliflozin (Forxiga) can now...

Quick-reference MIMS COPD prescribing resources updated

Quick-reference MIMS COPD prescribing resources updated

Concise MIMS resources on COPD management and antibiotic...